Glenmark Therapeutics Inc., USA, a subsidiary of Glenmark Pharmaceuticals Limited, has announced the launch of Adapalene Gel USP, 0.1% in new pump packs. This over-the-counter (OTC) product is a dermatological treatment that can be compared to the active ingredient found in Differin® Gel, 0.1%. The launch aims to enhance consumer convenience with an easy-to-use dispensing option, further strengthening Glenmark’s dermatology portfolio in the United States.
According to data from Nielsen, the market for Differin® Gel, 0.1% (OTC) achieved annual sales of approximately $45.8 million for the 52-week period ending September 5, 2026. This indicates a robust market presence for products within this category, highlighting the potential for Glenmark’s new offering. The introduction of the pump pack format is expected to cater to the evolving needs of consumers seeking high-quality and affordable healthcare solutions.
Marc Kikuchi, President and Business Head of North America for Glenmark, expressed that this launch underscores the company’s commitment to delivering innovative healthcare products that meet consumer demands. The new packaging is designed to improve the user experience by providing a more convenient application method, thereby enhancing the product’s appeal in the competitive U.S. dermatology market.
Glenmark Pharmaceuticals Limited, the parent company, is recognised globally for its focus on innovation and accessibility in the pharmaceutical industry. With a diversified portfolio that includes branded, innovative, generics, and consumer health products, Glenmark continues to expand its reach across various therapeutic areas such as respiratory, dermatology, and oncology. Analysts observe that Glenmark’s strategic initiatives, such as this product launch, are likely to bolster its market position and drive growth in the coming years.
